Email updates

Keep up to date with the latest news and content from BMC Research Notes and BioMed Central.

Open Access Case Report

Case report of exercise and statin-fibrate combination therapy-caused myopathy in a patient with metabolic syndrome: contradictions between the two main therapeutic pathways

Andrea László, László Kalabay* and János Nemcsik

Author Affiliations

Department of Family Medicine, Semmelweis University, Kútvölgyi str. 4, Budapest, 1125, Hungary

For all author emails, please log on.

BMC Research Notes 2013, 6:52  doi:10.1186/1756-0500-6-52

Published: 6 February 2013



Lifestyle modifications including exercise are beneficial and fundamentally part of the therapy of metabolic syndrome, although in most of the cases medical interventions are also required to reach the target values in the laboratory parameters. Statin and fibrate combination therapy is considered to be safe and effective in dyslipidaemia and metabolic syndrome. However, increased physical activity can enhance the statin and fibrate-associated myopathy. Myositis and the rare but life-threatening rhabdomyolysis are causing a conflict between exercise and statin-fibrate therapy, which is yet to be resolved.

Case presentation

We present a case of a 43-year-old Caucasian man with metabolic syndrome who had the side-effect of exercise and drug-associated myositis. The patient had only transient moderate complaints and rhabdomyolysis could be avoided with the one-month creatine kinase control, a test which is not recommended routinely by the new guidelines.


We would like to turn the spotlight on the possible complications of statin-fibrate therapy and exercise, when strict follow-up is recommended. In this condition high number of patients can be affected and the responsibility of general practitioners is accentuated.

Metabolic syndrome; Exercise; Statin-fibrate combination therapy; Myopathy; Creatine kinase